Results 21 to 30 of about 669,979 (252)
BMC Pulmonary Medicine, 2023 Background Pulmonary fibrosis (PF) is caused by a heterogeneous group of diseases, with a high inter-individual variability in disease trajectory. Identifying disease progression in patients with PF has impact on clinical management decisions.
Gizal Nakshbandi +9 more
doaj +1 more source
Interstitial Lung Diseases [PDF]
, 2009 The term interstitial lung disease (ILD) comprises a diverse group of diseases that lead to inflammation and fibrosis of the alveoli, distal airways, and septal interstitium of the lungs. The ILDs consist of disorders of known cause (e.g., collagen vascular diseases, drug-related diseases) as well as disorders of unknown etiology.
Christina Mueller-Mang +4 more
openaire +4 more sources
Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review
European Respiratory Review, 2021 Over the past three decades, an increasing number of publications have reported the association between interstitial lung disease (ILD) and anti-neutrophil cytoplasmic antibody (ANCA) or ANCA-associated vasculitis (AAV). With this increased awareness, we
Suha Kadura, Ganesh Raghu
doaj +1 more source
Annals of the Rheumatic Diseases, 2020 Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and connective tissue disease (CTD-ILD), such as rheumatoid arthritis-ILD and systemic ...
P. Spagnolo +9 more
semanticscholar +1 more source
Airway involvement in interstitial lung disease [PDF]
, 2006 PURPOSE OF REVIEW: After briefly discussing several ways to approach airway involvement in interstitial lung diseases - by diagnostic methodologies used to assess it, considering different topographical involvement, related to its presence in the diffuse
Robalo-Cordeiro, C
core +1 more source
Clusters of comorbidities in fibrotic hypersensitivity pneumonitis
Respiratory Research, 2022 Background Hypersensitivity pneumonitis (HP) is a type of interstitial lung disease (ILD) with a variable disease course and prognosis ranging from inflammatory and self-limiting to irreversible and progressive pulmonary fibrosis.
Thomas Skovhus Prior +4 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: Limited data are available regarding the entire spectrum of interstitial lung disease with a progressive fibrosing feature. We investigated the prevalence and prognostic predictive characteristics in patients with PF-ILD.Methods: This ...
Yuanying Wang +8 more
doaj +1 more source
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
New England Journal of Medicine, 2019 BACKGROUND Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis.
K. Flaherty +17 more
semanticscholar +1 more source
Acute exacerbations of fibrotic interstitial lung diseases
Respirology (Carlton South. Print), 2020 Acute exacerbation (AE) is a severe complication of idiopathic pulmonary fibrosis (AE‐IPF). In 2016, an international working group revised its definition and diagnostic criteria; however, few studies have assessed the frequency and prognosis of AE in ...
A. Suzuki +14 more
semanticscholar +1 more source
ANXA11 rs1049550 Associates with Löfgren’s Syndrome and Chronic Sarcoidosis
Cells, 2022 Sarcoidosis is an immune mediated granulomatous disease commonly affecting the lungs. Genome wide association studies identified many genomic regions that are shared among multiple immune mediated diseases.
Bekir Karakaya +5 more
doaj +1 more source